Camp4 Therapeutics Poration Stock Today
| CAMP Stock | USD 5.99 0.01 0.17% |
PerformanceGood
| Odds Of DistressLow
|
CAMP4 THERAPEUTICS is selling at 5.99 as of the 6th of January 2026; that is 0.17% down since the beginning of the trading day. The stock's last reported lowest price was 5.62. CAMP4 THERAPEUTICS has only a 7 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 8th of October 2025 and ending today, the 6th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of October 2024 | Category Healthcare | Classification Health Care |
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company was incorporated in 1981 and is headquartered in Irvine, California. The company has 46.88 M outstanding shares of which 453.47 K shares are currently shorted by private and institutional investors with about 3.22 trading days to cover. More on CAMP4 THERAPEUTICS PORATION
Moving against CAMP4 Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CAMP4 Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Joshua MandelBrehm | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Jakarta Stock Exchange, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Communication Equipment, Technology (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCAMP4 THERAPEUTICS can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CAMP4 THERAPEUTICS's financial leverage. It provides some insight into what part of CAMP4 THERAPEUTICS's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAMP4 THERAPEUTICS PORATION (CAMP) is traded on NASDAQ Exchange in USA and employs 55 people. CAMP4 THERAPEUTICS is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 200.18 M. CAMP4 THERAPEUTICS conducts business under Biotechnology sector and is part of Health Care industry. The entity has 46.88 M outstanding shares of which 453.47 K shares are currently shorted by private and institutional investors with about 3.22 trading days to cover.
CAMP4 THERAPEUTICS PORATION currently holds about 47.72 M in cash with (45.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29.
Check CAMP4 THERAPEUTICS Probability Of Bankruptcy
Ownership AllocationCAMP4 THERAPEUTICS holds a total of 46.88 Million outstanding shares. 30% of CAMP4 THERAPEUTICS PORATION outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Thereupon, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check CAMP4 Ownership Details
CAMP4 THERAPEUTICS Historical Income Statement
CAMP4 Stock Against Markets
CAMP4 THERAPEUTICS Corporate Management
| Kelly Gold | Chief Officer | Profile | |
| John Partain | Interim Experience | Profile | |
| Erik Schulz | Interim Officer | Profile | |
| Christian Horne | Interim Sales | Profile | |
| Brett Jackson | Senior Logistics | Profile | |
| Mark Gaydos | Chief Officer | Profile |
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.